HUYA Bioscience International Announces Regulatory Approval Of Chidamide, The First Selective HDAC Inhibitor In China
HUYA Bioscience International Announces Regulatory Approval Of Chidamide, The First Selective HDAC Inhibitor In China
HUYA holds exclusive rights to chidamide as HBI-8000 ex-China
San Diego, CA, USA – January 12, 2015 –HUYA Bioscience International (HUYA) announced today that Shenzhen Chipscreen Biosciences (Chipscreen) has obtained marketing approval from the Chinese FDA for the world’s first oral HDAC inhibitor, chidamide, for the treatment of relapsed or refractory peripheral T-cell lymphoma.